Efficacy and Safety of Basal Insulin Combined with GLP-1 Receptors Agonists versus Intensified Conventional Insulin Regimens in Type 2 Diabetes: A Meta Analysis of Randomized Controlled Trials
Abstract
Background / Aim: In Type 2 diabetes, Multiple Daily Injection (MDI) is effective but associated with hypoglycemia, weight gain, and poor adherence. Despite the growing endorsement of basal insulin plus GLP-1 receptor Agonist (GLP-1RA) as a streamlined therapeutic step-down, a pooled synthesis that encompasses every published randomized controlled trial investigating this comparator remains absent from the literature. Methods / Materials: A systematic review with meta-analysis was performed in line with PRISMA 2020 standards, and its protocol was prospectively registered in PROSPERO. Electronic searches were executed across PubMed, Scopus, Web of Science, and Cochrane Central with time horizon extending from database inception to the cut-off date of April 2026. Randomized controlled trials comparing de-intensification from MDI to basal insulin plus a GLP-1RA with continuation of MDI in diabetic type 2 adults were included. Pairwise meta-analyses were performed using random-effects models. Trial sequential analysis was applied to assess the sufficiency of accrued evidence. Using the GRADE System, we evaluated the level of certainly across the pooled effect estimates. PROSPERO ID: CRD420261443671. Results: Seven trials (1,397 patients) were included. There was no significant difference in HbA1c change between strategies (MD â'0.01 percentage points; 95% CI â'0.10 to 0.09; high certainty). The GLP-1RA-based strategy significantly reduced body weight (MD â'3.53 kg; 95% CI â'4.56 to â'2.49; moderate certainty), total daily insulin dose (MD â'33.47 units/day; 95% CI â'47.00 to â'19.95; very low certainty), and hypoglycemia risk (RR 0.67; 95 % CI 0.45 â" 0.98; moderate certainty). Gastrointestinal adverse events were more frequent with the GLP-1RA-based regimen (RR 2.29; 95% CI 1.27â"4.15; high certainty). Overall adverse event rates were similar between groups. Conclusion: For adults with type 2 diabetes, substituting MDI with a basal insulinâ"GLP-1RA combination sustains glycemic targets while mitigating weight gain, lowering insulin consumption, and attenuating hypoglycemic episodesâ"thereby reinforcing its role as an effective and safe simplification strategy.